Prediction Model for Lateral Lymph Node Metastasis

Radiomics-based Prediction Model for Lateral Lymph Node Metastasis in Rectal Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04635488

Enrollment

200

Registered

2020-11-19

Start date

2020-01-01

Completion date

2022-12-31

Last updated

2020-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

rectal cancer, lymph node metastasis, prediction model

Brief summary

Mid to low-lying rectal cancer patient with enlarged lateral lymph node befor treatment and receiving lateral lymph node dissection would be enrolled. Radiomics parameters of lateral lymph nodes would be extracted by expert software. Then a part of the nodes would be used as the training set to build the prediction model, and the another part nodes would be used as the validation set.

Detailed description

After performing lateral lymph node dissection for the enrolled patients, we would find the targeted lateral node which was matched with the enlarged one in imaging from the specimen. Then the nodes would be send for pathological examination. Then we would extract the radiomics parameters of the nodes from the pretreatment CT and MRI with ITK-SNAP software. According to the pathological status, lymph nodes and corresponding radiomics parameters would be divided into positive and negative groups. Then significant parameters would be selected by R software. Then the prediction model with nomogram would be developed. 70% nodes would be used for for model development and the other 30% would be used for validation.

Interventions

PROCEDURElateral lymph node dissection

All participted would receive lateral lymph node dissection for rectal cancer.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* middle to low-lying rectal adenocarcinoma patients with enlarged lateral lymph node ≥5mm for short diameter in CT and/or MRI

Exclusion criteria

* other kind of rectal tumor including neuroendocrine and malignant. * high location rectal cancer. * recurrent rectal cancer

Design outcomes

Primary

Measure	Time frame
metastasis rate of lateral lymph node	2020.1-2022.12.31

Countries

China

Contacts

Primary ContactZiqiang Wang, MD

wangziqiang@scu.edu.cn18980602028

Backup ContactXubing Zhang, MD

2421770462@qq.com18428374478

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026